CLINICAL TRIALS PROFILE FOR OMAVELOXOLONE
All Clinical Trials for omaveloxolone
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02029729 ↗ | RTA 408 in the Treatment of Advanced Solid Tumors (NSCLC & Melanoma) - DISCOVER | Completed | AbbVie | Phase 1 | 2013-12-01 | This proposed first-in-human study (408-C-1303) is designed to assess the safety, maximum tolerated dose, pharmacodynamics, and pharmacokinetics of omaveloxolone (RTA 408) in patients with advanced solid tumors that are refractory after standard of care therapy for the disease. The results of this study will help provide clinical information for the design and conduct of further clinical studies with RTA 408 in cancer patients. |
| NCT02029729 ↗ | RTA 408 in the Treatment of Advanced Solid Tumors (NSCLC & Melanoma) - DISCOVER | Completed | Reata Pharmaceuticals, Inc. | Phase 1 | 2013-12-01 | This proposed first-in-human study (408-C-1303) is designed to assess the safety, maximum tolerated dose, pharmacodynamics, and pharmacokinetics of omaveloxolone (RTA 408) in patients with advanced solid tumors that are refractory after standard of care therapy for the disease. The results of this study will help provide clinical information for the design and conduct of further clinical studies with RTA 408 in cancer patients. |
| NCT02128113 ↗ | RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD | Completed | AbbVie | Phase 2 | 2014-05-01 | This study assesses the efficacy and safety of two concentrations of omaveloxolone (RTA 408) ophthalmic suspension for the prevention of corneal endothelial cell loss following cataract surgery. |
| NCT02128113 ↗ | RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD | Completed | Reata Pharmaceuticals, Inc. | Phase 2 | 2014-05-01 | This study assesses the efficacy and safety of two concentrations of omaveloxolone (RTA 408) ophthalmic suspension for the prevention of corneal endothelial cell loss following cataract surgery. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for omaveloxolone
Condition Name
Clinical Trial Locations for omaveloxolone
Trials by Country
Clinical Trial Progress for omaveloxolone
Clinical Trial Phase
Clinical Trial Sponsors for omaveloxolone
Sponsor Name
